(Reuters) – The World Health Organization said on Tuesday that data shows resistance to the drug is growing in patients receiving GSK’s HIV drug, dolutegravir.
GSK did not immediately respond to a Reuters request for comment.
(Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
Comments